(firstQuint)Study to Evaluate Safety, Tolerability, and Pharmacokinetics of UB-621 in Healthy Volunteers.

 This is a phase I, open-label, single dose, dose escalation study in healthy volunteers.

 Eligible volunteers will be sequentially enrolled into four escalating-dose cohorts at a study site.

 After administration of a single subcutaneous dose of UB-621, subjects will be followed for 70 or 112 days and monitored for safety, tolerability, and pharmacokinetics parameters.

.

 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of UB-621 in Healthy Volunteers@highlight

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of a single subcutaneous dose of UB-621 in healthy volunteers.

